OS Therapies Announces Positive Safety Data from Phase I Clinical Trial of OST-HER2 in HER2-Expressing Breast Cancer and in Preclinical Efficacy in Models of Breast Cancer

By
Emily Salmini
-
0
70
OS Therapies, Inc. announced positive data from a Phase I clinical trial of OST-HER2 in patients with HER2-expressing solid tumors in breast cancer and other cancers.
[OS Therapies, Inc. (BusinessWire)]
Press Release